MedTrace Logo

A Study of Intranasal ChAdOx1 nCOV-19

NCT04816019 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-10-24

No results posted yet for this study

Summary

Open label, dose escalation study to investigate:

1. Safety, tolerability and immunogenicity of one or two doses of intranasal ChAdOx1 nCOV-19, in vaccine naïve individuals, with randomisation between one and two dose groups.
2. Safety, tolerability and immunogenicity of intranasal ChAdOx1 nCOV-19, given as a booster dose in individuals who have had two intramuscular COVID-19 vaccinations.

Conditions

  • Coronavirus

Interventions

BIOLOGICAL

ChAdOx1 nCov-19

A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Alexander Douglas, Dr · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816019 on ClinicalTrials.gov